As World Awaits Results From Remdesivir Trials, Pricing Questions Loom
April
9
Hydroxychloroquine and chloroquine are far from the only drugs being tested for their potential to treat COVID-19, the disease caused by the novel coronavirus that has ballooned into a pandemic.
Another potentially promising therapy is remdesivir, an experimental antiviral drug developed by California-based Gilead Sciences, Inc. Previously, it has been tested on patients infected with Ebola and two other coronaviruses: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
© 2021 MMIT
The Latest
-
With COVID Testing Set to Surge, In...
October 22, 2021 -
Could Payers, Plan Sponsors Pick Re...
October 22, 2021 -
UnitedHealthcare, Cigna Join ‘Vir...
October 22, 2021
Meet Our Reporters
-
Jill Brown Kettler Executive Editor
View Jill Brown Kettler's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile